Under PLI Scheme company was awarded two important licenses - B1 & B6. What is the current status?
We were rewarded the project of Aatmanirbhar Bharat Rojgar Yojana Under PLI Scheme and we have successfully achieved our first milestone of developing the sample for the molecule VITAMIN B1 (Thiamine Hydrochloride). It was developed from Base Root till Finish Product and we have successfully manufactured all the Intermediated Products which is required to manufacture the finish API - VITAMIN B1.
We are proud to say that we happened to be the only company that got two API, in one basket under PLI scheme. We developed the products in our R&D and it would be our monopoly products and we have started the process to file for Patent for the manufacturing process and the intermediates. For Vitamin B1 and B6 and other API/ intermediates the production facility is under process and in March 2026 we will finalise the full facility of Mahad plant which is not only for PLI scheme rather it is a multipurpose plant. If we include the recovery of solvent plant, it houses total five plants under one roof. Our projection is to achieve sales of Rs 150 crore in the first year and profit to be above 30% which will reflect in FY26-27.
Ratna Life Sciences presented a significant growth opportunity for the company. What is the future expansion plan that could drive revenue potential?
We acquired 100 per cent stake in Ratna Lifesciences and now it is a wholly owned subsidiary of Sudarshan Pharma. Ratna Lifesciences specialises in oncology products with an existing capacity of two metric tons, expandable to 15 metric tons. The acquisition helped our immediate foray into Oncology products with a manufacturing unit which is already setup, with option to expand further. We believe oncology business to become a major share of revenues over the next 3-5 years.
Bu hikaye Indian Economy & Market dergisinin November 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Indian Economy & Market dergisinin November 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
WORLD DEVELOPMENT REPORT 2024 THE MIDDLE-INCOME TRAP
A World Bank report titled 'World Development Report 2024: The Middle-Income Trap' indicates that India may take up to 75 years to attain just a quarter of the United States' per capita income. The insights in the report provides a useful reality check for India's ambitious goals, such as becoming a developed economy by 2047 or reaching a $5 trillion economy within the next three years.
IN CONVERSATION: "We are working with a Vision 2035. I'm sure within next 5 years we will be ranking among the Fortune 500 companies.”
Sudarshan Pharma Industries Ltd., led by its promoters, Mr. Hemal V. Mehta, a chemical engineer, and Mr. Sachin V. Mehta, has established a strong foundation in specialty chemicals and bulk drugs. Their relentless enthusiasm is visible when they speak. Indian Economy & Market reached out, to piece together the company's achievements and new initiatives in detail.
Sudarshan Pharma Industries Ltd. A MULTIBAGGER IN MAKING
Sudarshan Pharma Industries Ltd. operates across various sectors in both the pharmaceutical and chemical industries, with a focus on specialty chemicals and intermediates, which find applications in Indian Le pharmaceuticals, paints, food products, and adhesives.
MUTUAL FUND LITE OR MF LIT PROMISING PROGRESS FOR INVESTORS
The SEBI has streamlined rules for passively managed schemes to have the impact of letting more players in the mutual fund ecosystem and offering diversified, low-risk investment options to retail investors. It would increase market liquidity and attract participation from old as well as new Asset Management Companies (AMCs). Shivanand Pandit feels that MF Lite is going to democratize investment opportunities in the Indian financial market.
GLOBALISM, FREEDOM & DEMOCRACY DO NOT MIX
The world today is packed with wealthy institutions and individuals that stand in revolt against the ideas of freedom and democracy. They do not like the idea of geographically constrained states with zones of juridical power.
BRICS Member States Ready to Dethrone Dollar
AS the US weaponises the dollar in the Russian and Iranian sanctions, there is increasing desire by other developing countries to seek alternative currencies for trade, investment, and reserves, as well as developing alternative multilateral clearance systems outside of SWIFT.
7 BEST PHARMA COMPANIES
The pharmaceutical industry in India is expected to reach $65 Bn by end of 2024 and to $130 Bn by 2030. India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports. While Nifty's performance has been lackluster over the past month, several pharmaceutical stocks have shown resilience.
NEW INVESTMENT PRODUCT CATEGORY IS SEBI'S LATEST MOVE COMMENDABLE?
The Securities and Exchange Board of India (SEBI) has introduced a consultation paper proposing a new investment product category aimed at addressing a specific market need. This proposed asset class would offer investment options that sit between mutual funds (MFS) and PMS, filling a gap and providing greater flexibility in portfolio management. The new investment vehicle is designed for investors who are prepared to take on riskier market positions but find PMS schemes or AIFs out of reach. SEBI after reviewing the feedback and finalizing the regulations through stakeholder discussions, may issue the final regulations.
DECODING THE CHINA MYTH
Myths die hard. Among these is the great myth that China's poised to take over the world. Here, James Rickards debunks that myth.
What Is In Store For The Indian Economy?
Until the 2014 Lok Sabha elections, when the Bharatiya Janata Party secured 282 seats and Narendra Modi ascended to power, India experienced 21 years of coalition governments. A decade later, the BJP holds 240 seats in the Lok Sabha, and India is once again governed by a coalition. Fitch has indicated that coalition politics and a weakened mandate for the NDA could hinder the passage of ambitious reform legislation. It raises the question: Do coalition governments impede the economic reform agenda?
